PTPN11 and plasma cell myeloma: Furthermore, we observed that both two SHP2 inhibitors treatment decreased p-SHP2 and p-ERK protein levels, while they induced protein levels of SHP2, ERK, P21, BAK, and cleaved caspase-3 in BTZ-resistant myeloma cells (Figures 8E,F).